Biotechnology is at a turning point: With the planned EU Biotech Act, regulation is moving to centre stage. Companies are seeking clarity regarding regulatory frameworks, financing opportunities, and market access. At the same time, the US BioSecure Act is intensifying international competitive pressure — Europe must act now to secure its role in the global biotech landscape.
While public support for the biotech sector is facing growing domestic political scrutiny in the United States, transatlantic trade continues to be strained by trade policy tensions. Arbitrary tariffs and export restrictions are creating uncertainty and jeopardising international partnerships and supply chains. Europe must respond decisively to secure access to key markets and remain globally competitive.
Companies are confronted with crucial questions: What real impetus does the EU Biotech Act offer for growth and investment? How can successful partnership models be established? What strategies will ensure market access in an increasingly dynamic environment?
Biotechnology is a pivotal industry with immense growth potential. Personalised medicine, industrial biotechnology, and data-driven business models are driving innovation, economic development, and solutions to global challenges. Now is the time to chart the right course — to stay connected to international markets and to strengthen Europe’s position as a biotechnology hub in the long term.
Speaker
Dr. Hubert BirnerManaging Partner und Gesellschafter – TVM Capital Life Science (TVM)Mehr Informationen
Prof. Dr. Christof von KalleBIH-Chair für Klinisch-Translationale Wissenschaften und Gründungsdirektor des gemeinsamen Clinical Study Centers von BIH und CharitéMehr Informationen
Prof. Dr. Helga Rübsamen-SchaeffGründerin & ehemalige CEO – Mitglied des Aufsichtsrats AiCuris AG
Dr. Sylvia WojczewskiCEO und Miteigentümerin – BioSpring Gesellschaft für Biotechnologie mbH
Regional Strength, Global Impact: How Locations Retain Talent
PANEL DISCUSSION
Alexander LeutnerCo-CEO & Co-Founder – Cellbricks Therapeutics
Prof. Dr. Christof von KalleBIH-Chair für Klinisch-Translationale Wissenschaften und Gründungsdirektor des gemeinsamen Clinical Study Centers von BIH und CharitéMehr Informationen
Dr. Sylvia WojczewskiCEO und Miteigentümerin – BioSpring Gesellschaft für Biotechnologie mbH
Additional speakers to be confirmed
Business Models, Scaling, and Market Access
12:05
Profitable and Crisis-Proof: Which Business Models Ensure Long-Term Success in Biotechnology?
PANEL DISCUSSION
Dr. Hubert BirnerManaging Partner und Gesellschafter – TVM Capital Life Science (TVM)Mehr Informationen
Dr. Andreas EckertGeschäftsführender Gesellschafter – Eckert Wagniskapital und FrühphasenfinanzierungMehr Informationen
Dr. Friedemann JanusSVP, Head of Regional Business Development & Licensing, Co.Lab and Divestitures – BayerMehr Informationen
Orsolya SymmonsProgramme Manager for Health and Biotechnology – European Innovation Council and SMEs Executive Agency (EISMEA)Mehr Informationen
12:40
Lunch Break
14:00
Strategically Lean: The Advantages of Specializing in a Single Target
BEST PRACTICE
Dr. Jan PothManaging Director & CEO – SciRhom GmbHMehr Informationen
14:15
From Clinical Phase to Successful Market Launch: Steps and Pitfalls
BEST PRACTICE
Dr. Stefan BlesseCSO – Granzer Regulatory Consulting & Services
14:30
Rethinking Global Partnerships: Biotech Alliances Between Europe and Asia – Between Strategic Autonomy and Profitable Expansion
PANEL DISCUSSION
Dr. Jasmina KirchhoffProjektleiterin für Pharmastandort Deutschland – Institut der deutschen WirtschaftMehr Informationen
Andreas PollnerGeneral Manager – Moderna GermanyMehr Informationen
Oliver SchenkMitglied des Europäischen Parlaments
Stefan WeberCEO – Newron Pharmaceuticals, S.p.A.Mehr Informationen
15:05
Networking Break
Partnerships, Funding, and Investor Strategies
15:45
Finding Partners, Securing Capital, Strengthening Europe: Action Areas for Biotechnology Today
IMPULSE TALK
Dr. Klaus MaleckCFO von ITM Radiopharma und Vorstand – BIO Deutschland
16:00
Scaling Science: Europe’s Roadmap to More Growth Capital for Biotech
FIRESIDE-CHAT
Kristin SchreiberDirector for Chemicals, Health, Retail and Agrifood at European Commission – DG GROWMehr Informationen
16:15
Beyond Capital: Strategic Investments for a Resilient European Biotech Sector
PANEL DISCUSSION
Kristin SchreiberDirector for Chemicals, Health, Retail and Agrifood at European Commission – DG GROWMehr Informationen
Dr. Achim PlumGeschäftsführer – HTGFMehr Informationen
Prof. Dr. Angela RelógioCo-founder & CEO – TimeTellerMehr Informationen
16:50
Smart Money & Resilient Alliances: Funding Strategies for the Next Biotech Wave
PANEL DISCUSSION
Claudia BlattnerVice President Business Development – Immatics
Dr. Elisa KiebackChief Technology Officer – T-knifeMehr Informationen
Dr. Fei TianPrincipal – MIG CapitalMehr Informationen
17:20
Longevity: The Next Billion-Dollar Field – What Can Europe Offer?
POWERTALK
Dr. Isabelle SchifferInvestment Manager – b.value
17:35
LIVE BROADCAST
Felix HoltermannU.S. Bureau Chief – HandelsblattMehr Informationen
17:45
Summary
Helena SmolakRedakteurin Pharma – Handelsblatt
Dr. Christian KannemeierSenior Investment Manager – HTGF
Dr. Hubert BirnerManaging Partner und Gesellschafter – TVM Capital Life Science (TVM)
Dr. Birner ist Managing Partner und Gesellschafter bei TVM Capital Life Science (TVM), einer führenden internationalen Venture-Capital-Gesellschaft mit Fokus auf Innovationen in den Life Sciences. Er ist verantwortlich für die übergeordnete Investitionsstrategie von TVM sowie für den globalen Fondsbetrieb.
Derzeit ist er Vorsitzender des Verwaltungsrats von AL-S Pharma AG, Centogene AG, leon nanodrugs GmbH, Smart Reporting GmbH und Spepharm Holdings BV. Zuvor war Dr. Birner unter anderem Mitglied des Verwaltungsrats von Acer Therapeutics, Argos Therapeutics, Horizon Pharma Inc., Bioxell SA, Evotec AG, Jerini AG, Direvo Biotech AG, Probiodrug AG und Proteon Therapeutics Inc.
Vor seiner Tätigkeit bei TVM ab dem Jahr 2000 war er Leiter Business Development Europe und Marketingdirektor Deutschland bei Zeneca. Zu Zeneca kam Dr. Birner von der europäischen Healthcare- und Pharma-Praxis der Unternehmensberatung McKinsey & Company, wo er umfassende Erfahrung in den Bereichen F&E-Management, Marketing und Vertrieb, Joint-Venture-Strukturierung und Business Development sammelte.
Vor dem Einstieg in die Wirtschaft war Dr. Birner in der akademischen Forschung tätig – unter anderem als Assistenzprofessor für Biochemie an der Ludwig-Maximilians-Universität München (LMU), wo er zuvor mit summa cum laude promoviert hatte. Seine Dissertation wurde mit dem Hoffmann-La Roche-Preis für herausragende Grundlagenforschung im Bereich Stoffwechselkrankheiten ausgezeichnet. Darüber hinaus besitzt Dr. Birner einen MBA der Harvard Business School.
Prof. Dr. Christof von KalleBIH-Chair für Klinisch-Translationale Wissenschaften und Gründungsdirektor des gemeinsamen Clinical Study Centers von BIH und Charité
Prof. Dr. Christof von Kalle ist seit Juni 2019 BIH-Chair für Klinisch-Translationale Wissenschaften und Gründungsdirektor des gemeinsamen Clinical Study Centers von BIH und Charité und zudem seit 2025 Direktor des Luxembourg Center for Translational Research. Der Wissenschaftler und Unternehmer mit klinischem Hintergrund in der Hämatologie/Onkologie ist seit 2024 Sachverständiger im Aufsichtsrat des Universitätsklinikums Freiburg und war von 2019 bis 2023 Mitglied im Sachverständigenrat zur Begutachtung der Entwicklung im Gesundheitswesen. Zuvor war er von 2005 bis 2018 als Gründungsdirektor des Nationalen Centrums für Tumorerkrankungen (NCT) Heidelberg und Leiter der Abteilung Translationale Onkologie am Deutschen Krebsforschungszentrum (DKFZ).
Dr. Mridul AgrawalCEO & Co-Founder – iuvando Health, Boston
Dr. Mridul Agrawal is a physician-scientist, healthcare entrepreneur, and transatlantic business leader driving the future of cancer care through human-centered health technology innovation.
A recipient of the prestigious German Academic Scholarship Foundation Award, Dr. Agrawal studied medicine and health economics at Heidelberg University, complemented by academic training at Johns Hopkins University and the University of Zurich. He pursued clinical training in hematology and medical oncology in Germany, followed by a postdoctoral fellowship at the Dana-Farber Cancer Institute and Harvard Medical School in Boston, supported by the German Research Foundation.
As CEO and Co-Founder of iuvando Health, Dr. Agrawal is redefining how cancer patients gain access to cutting-edge clinical trials. Under his leadership, iuvando has received numerous accolades, including the German Startup Award, the EY Public Value Award for societal impact, and the EIT Health Headstart Award for European healthcare innovation.
Beyond entrepreneurship, Dr. Agrawal is a recognized thought leader shaping the global health innovation agenda. He is a Fellow of the Sciana Health Leaders Network at Salzburg Global and a member of Atlantik-Brücke, where he actively promotes transatlantic dialogue on healthcare policy and innovation. He also advises organizations such as the German-American Business Council, the German Accelerator and GAIN among many others, and regularly engages with top-level policymakers and C-level leaders across industry, healthcare and academia. His perspectives on healthcare innovation, technology, and entrepreneurship are featured in leading international media outlets.
Maike TelghederRedakteurin Unternehmen & Märkte – Handelsblatt
Maike Telgheder schreibt von Frankfurt aus über Gesundheitsunternehmen. Beim Handelsblatt arbeitet sie seit 1999. Zuvor hatte Telgheder unter anderem bei der Marketingfachzeitung „Horizont“ das Ressort Unternehmen geleitet.
Johannes Fruehauf MD PhDPresident & CEO Biolabs und Founder & Chairman – LabCentral
Johannes Fruehauf MD, PhD is a physician-scientist and life-science entrepreneur. He is the Founder and CEO of BioLabs and Founder and Executive Chairman of LabCentral, the leading international network for co-working laboratory spaces for life-science startup companies. Together, BioLabs/LabCentral have helped launch over 850 primarily venture funded startup companies in the life sciences in 17 different cities with a presence in the United States, Germany, France and Japan. The concept of these facilities is built around openness, transparency and shared resources and has changed the way biotech companies are built around the world. Companies launched at BioLabs/LabCentral have raised over $30bn while in residence since 2010. LabCentral and BioLabs were also the recipient of the prestigious Prix Galien Award in 2022 for the best biotech startup launchpads in the “Incubators, Accelerators and Equity” category.
Dr. Fruehauf is also a Founding General Partner at Mission BioCapital, an early-stage venture capital fund providing capital to start-up companies in the life sciences. MBC collaborates closely with lab partners to offer support/expertise and opportunities for funding to both resident companies in the lab network including BioLabs, LabCentral and MBC BioLabs in San Francisco and additional high-quality start-ups.
Dr. Fruehauf studied medicine in Germany and France, while also conducting field work in Africa (Zimbabwe and Guinea). Thereafter, he practiced medicine (internal medicine and OB/Gyn) for several years in Germany before coming to Boston for a post-doc at Beth Israel Deaconess Medical Center/Harvard Medical School. He is a graduate of the University of Frankfurt and received his doctorate from the University of Heidelberg. He is also the author of over 30 peer reviewed publications and is named inventor on 9 issued patents on drug delivery and RNAi-based therapeutics.
Dr. Andreas SchmidtManaging Director – Springboard Health Ventures
Dr. Andreas Schmidt is a serial entrepreneur with a track record of building deep tech startups across Asia, Europe, and the United States. He is the Managing Director of Springboard Health Ventures, a venture capital firm and global angel network focused on health technology innovation.
After successfully leading Proteona to its acquisition by Singleron Biotechnologies, he assumed responsibility for global business development at Singleron, driving the application of single-cell technologies in precision medicine.
Dr. Schmidt is actively involved in multiple startups worldwide as a board member, mentor, and shareholder. He holds a PhD in Immunology from the University of Cologne and UC Berkeley, and was among the early entrepreneurs within the Singapore-MIT Alliance for Research and Technology (SMART) initiative.
Rodger NovakCo-founder – CRISPR Therapeutics
Rodger Novak is a serial entrepreneur and senior executive in the pharmaceutical and biotech industries. He co-founded CRISPR Therapeutics in 2013 with Shaun Foy and Emmanuelle Charpentier, led its IPO in 2016 as CEO, and later served as President and Chairman until 2023.
Previously, Rodger was Global Head of Infectious Diseases at Sanofi. Before that he co-founded Nabriva Therapeutics in 2006, a spin-out from Sandoz/Novartis, where he had served as Vice Head of the Antibiotic Research Institute.
He currently chairs the boards of Econic Biosciences and AiRNA Therapeutics and is a director of ERS Genomics, which he co-founded in 2014.
Rodger earned his M.D. from Philipps University, Marburg, Germany and completed postdoctoral research at Rockefeller University, the Skirball Institute, and St. Jude Children’s Research Hospital. In 2001, he became a tenured Professor of Microbiology at the Vienna Biocenter. He has published widely, including in Nature, Nature Medicine, and Molecular Cell.
Dr. Andreas EckertGeschäftsführender Gesellschafter – Eckert Wagniskapital und Frühphasenfinanzierung
geboren 1960 in Berlin, Studium der Sozial- und Wirtschaftswissenschaften in Heidelberg, New York und Berlin, danach Kulturjournalist für die Deutsche Presse-Agentur und anschlie-ßend etliche Jahre Tätigkeit als „Information Officer“ für das Generalsekretariat der Vereinten Nationen in New York, Lateinamerika, Asien und Afrika.
Nach der Wende gründete Eckert über seine Eckert Wagniskapital und Frühphasenfinanzie-rung GmbH zahlreiche Unternehmen im Pharmasektor, unter anderem die Eckert & Ziegler Strahlen- und Medizintechnik AG (www.ezag.de), den Medikamentenentwickler Glycotope (www.glycotope.com) und den Pharmagroßhändler AEP (www.aepdirekt.de). Als Aufsichtsrat überwacht er gegenwärtig die Geschäfte der Bauerfeind AG sowie der beiden im Prime Stan-dard notierten Pentixapharm Holding AG und Eckert & Ziegler SE
Dr. Friedemann JanusSVP, Head of Regional Business Development & Licensing, Co.Lab and Divestitures – Bayer
Friedemann Janus, PhD, is a seasoned leader in the pharmaceutical industry, boasting over two decades of expertise that spans business development, licensing, strategy, divestments, commercial operations, and consulting. Currently, he serves as the Senior Vice President and Regional Head of Business Development & Licensing at Bayer, where he is at the forefront of innovative initiatives that bridge global and regional markets to foster groundbreaking advancements in healthcare.
In his current role, Dr. Janus and his team focus on three pivotal areas. First, they develop regional strategies that connect to local innovation ecosystems, access external innovations, identify and execute licensing opportunities, and manage alliances through Bayer’s Collaborate to Cure Hubs in China and Japan. Second, Dr. Janus leads Bayer Co.Lab, a state-of-the-art incubator network with sites in Cambridge (U.S.), Berlin (Germany), Kobe (Japan), and Shanghai (China), which nurtures transformative healthcare startups. Third, he oversees all out-licensing and divestiture activities for Bayer’s Pharmaceutical division, driving portfolio optimization and corporate growth.
Before his current role in BD&L, Dr. Janus was instrumental in launching Xarelto in its chronic indications as Vice President & Global Head of Commercial and Global Head of Launch Management. His strategic leadership significantly expanded Xarelto’s market presence, establishing it as a leading therapeutic option worldwide.
Prior to joining Bayer, Dr. Janus was a Partner at McKinsey & Company, where he supported Life Science companies across the US and Europe. His work focused on innovation and commercial strategies, helping these companies achieve growth and operational excellence.
Dr. Janus holds a PhD in Molecular Biology from the Heinrich Pette Institute for Experimental Virology at Hamburg University in Germany. His strong scientific foundation and innovative mindset have been crucial in driving his successful career in the pharmaceutical industry.
Orsolya SymmonsProgramme Manager for Health and Biotechnology – European Innovation Council and SMEs Executive Agency (EISMEA)
Orsolya is a programme manager with over 15 years overall experience in biomedical research, biotechnology and science management, devoted to advancing the European biotechnology and healthcare innovation ecosystem. She joined the EIC in 2024 as Programme Manager for Health and Biotechnology, having previously worked on the Innovative Health Initiative for COCIR, one of the partnership’s founding industry trade associations.
Orsolya’s research background is in molecular biology, with a PhD from EMBL and the University of Heidelberg (Germany), postdoctoral work at the École normale supérieure de Lyon (France) and the University of Pennsylvania (USA), and additional research experience in Hungary and the UK. She subsequently transitioned to research management, working as scientific coordinator and as head of fish facility at the Max Planck Institute for Biology of Ageing in Germany, before moving to the Brussels environment.
She also co-founded a successful Hungarian biotech company, providing her with insight of the practical hurdles of developing a small business in Europe to the point of sale.
Dr. Jan PothManaging Director & CEO – SciRhom GmbH
Senior Leader with more than 20 years of broad Pharma experience spanning a number of Therapeutic Areas (Specialty as well as Primary Care) and the complete value chain – from early drug development to commercialization with full P&L responsibility. Strong strategic thinking and analytical skills coupled with a track record of leading cross-functional teams in a matrix organization or as a direct line manager. Excellent interpersonal and communication skills with the ability to motivate, guide and align cross-cultural teams with the goal to achieve excellent results within the given timelines and constraints of a task.
Dr. Jasmina KirchhoffProjektleiterin für Pharmastandort Deutschland – Institut der deutschen Wirtschaft
geboren 1977 in Lübbecke; Studium der Volkswirtschaftslehre an der Universität Bielefeld; von 2003 bis 2009 wissenschaftliche Mitarbeiterin am Lehrstuhl für Volkswirtschaftspolitik der Universität Bielefeld; 2006 Forschungsaufenthalt an der Universität Lund, Schweden; 2009 Promotion zu Nationalen Innovationssystemen in Transformationsländern an der Universität Bielefeld. Seit September 2009 am Institut der deutschen Wirtschaft Köln im Themencluster Staat, Steuern und Soziale Sicherung. Bis Januar 2021 war sie hier als Senior Economist an der Forschungsstelle Pharmastandort Deutschland und im Themenfeld Gesundheitswirtschaft tätig. Seit Februar 2021 ist sie als Projektleiterin für die Forschungsstelle Pharmastandort Deutschland verantwortlich.
Andreas PollnerGeneral Manager – Moderna Germany
Andreas Pollner (Jahrgang 1973) ist seit Mai 2024 General Manager der Moderna Germany GmbH. Vor seinem Eintritt bei Moderna war Pollner mehr als 15 Jahre bei der Bayer AG in führenden Positionen tätig.
Als Senior Advisor, Artificial Intelligence (AI) in Marketing and Sale, Commercial Operations EMEA leitete er ein strategisches Projekt zur Integration von AI-Tools in kommerzielle Abläufe.
Zuvor war er Cluster Division Head Pharma – South. Med & Black Sea sowie Managing Director Bayer Hellas AG, Greece. Pollners umfangreiche Erfahrung in der Gesundheitsbranche und sein tiefes Verständnis für die Vermarktung pharmazeutischer Produkte bilden die Grundlage für das Wachstum von Moderna in Deutschland, welches er gemeinsam mit dem gesamten Team beschleunigen wird. Sein Diplom in Volks- und Betriebswirtschaftslehre erwarb Pollner an der Universität Witten/Herdecke, Deutschland und Universidad de Concepción, Chile.
Stefan WeberCEO – Newron Pharmaceuticals, S.p.A.
Stefan Weber was appointed Chief Executive Officer and Executive Director of Newron in 2012. He had been Chief Financial Officer of the Company since April 2005. Stefan holds a master’s degree in business management from FernUniversität Hagen (Diplom-Kaufmann). He has more than 30 years of industry experience in finance and general management. From 2001 to 2005, he was the Chief Financial Officer of Biofrontera, a company active in drug discovery and development. He joined Girindus, a fine chemistry process development and scale-up provider, in 1999, and was appointed Chief Financial Officer in 2000. From 1987 to 1999, he was with Lohmann Group, a worldwide producer of pharmaceutical, medical, technical and consumer products. His final position was Head of Finance of the Group. Stefan has executed numerous major financing transactions, debt, equity and mezzanine as well as national and European grants. He has also executed successful IPOs to the Frankfurt and Zurich stock exchanges and has been involved in a number of M&A transactions, divestments and strategic restructurings. He is German.
Kristin SchreiberDirector for Chemicals, Health, Retail and Agrifood at European Commission – DG GROW
Kristin Schreiber leads the Directorate F: Chemicals, Food, Retail, Health in DG GROW, the Directorate General for Internal Market, Industry, Entrepreneurship and SMEs.
Professional experience
Prior to her current Director position, she served as Director for Governance of the Single Market and International Affairs in DG MARKT (until 2015) and Director for SME policy in DG GROW (until March 2021).
Kristin Schreiber was Head of Cabinet of Employment Commissioner Vladimir Špidla, Deputy Head of Cabinet of Internal Market Commissioner Michel Barnier and member of the Cabinets of Enlargement Commissioner Günter Verheugen and Competition Commissioner Karel Van Miert. She also served as Head of Unit for International Affairs in DG Employment and Social Affairs and was a member of the Merger Task Force of DG Competition.
Education
After graduating with honours from L’Institut d’Etudes Politiques de Paris and gaining a Master’s degree from the University of Kent at Canterbury and the Diplôme des Etudes Approfondies of the College of Europe in Bruges in International Relations, Economics and European Law, she worked as a researcher on the Single Market at the Institut für Europäische Politik in Bonn, before joining the European Commission as policy officer on biotechnology in 1990 where she held a large variety of positions since.
Other relevant information
Kristin speaks German, French, English and Spanish.
She is Member of:
– the management board of the European Chemical Agency (ECHA).
– the Innovative Health Initiative Joint Undertaking Governing Board (IHI JU)
– the Circular Bio-Based Europe Joint Undertaking Governing Board (CBE JU)
– the Global Health Joint Undertaking Governing Board (EDCTP3)
Dr. Achim PlumGeschäftsführer – HTGF
Dr. Achim Plum, seit Januar 2025 Geschäftsführer des High-Tech Gründerfonds (HTGF), bringt über zwanzig Jahre Erfahrung und ein großes Netzwerk in der Life-Sciences-Industrie mit. Der promovierte Genetiker kombiniert wissenschaftliche Expertise mit umfassenden Managementkenntnissen. Er verfügt über tiefe Expertise u.a. in den Bereichen Diagnostik, Präzisionsmedizin, Life Science Tools und Medizintechnik.
In seiner Laufbahn hat er in Führungspositionen bei Unternehmen in der Früh- und Wachstumsphase sowie global agierenden Technologiekonzernen erfolgreich Prozesse aufgebaut, Strukturen geschaffen und Organisationen durch starkes Wachstum geführt.
Dr. Plum hat zwei Börsengänge begleitet und verfügt über fundierte Kenntnisse in der Finanzierung von Unternehmen in allen Entwicklungsstadien.
Prof. Dr. Angela RelógioCo-founder & CEO – TimeTeller
Prof. Dr. Angela Relógio ist Professorin für Systemmedizin und Leiterin des Instituts für Systemmedizin an der MSH Medical School Hamburg sowie der Gruppe für Chronobiologie und Krebs-Systembiologie. Zuvor war sie an der Charité – Universitätsmedizin Berlin tätig. Sie ist Gründerin der TimeTeller GmbH, einem MedTech-Startup für personalisierte zirkadiane Analysen, und Autorin des Buches „Die Chrono-Strategie“. Ihre Arbeit verbindet wissenschaftliche Exzellenz mit praktischer Anwendung, um Gesundheit, Prävention und personalisierte Medizin voranzutreiben. Ursprünglich aus Portugal, lebt und arbeitet sie in Deutschland.
Zu TimeTeller:
TimeTeller® revolutioniert die personalisierte Medizin, indem es die innere Uhr des Menschen entschlüsselt. Mithilfe von RNA-Analysen aus Speichelproben, Künstlicher Intelligenz und mathematischer Modellierung bestimmt TimeTeller® den individuellen zirkadianen Rhythmus und identifiziert den optimalen Zeitpunkt für die Medikamenteneinnahme. Dadurch kann die Wirksamkeit von Therapien, insbesondere in der Krebsbehandlung, verdoppelt und Nebenwirkungen um das bis zu Fünffache reduziert werden. Neben der medizinischen Anwendung unterstützt TimeTeller® auch die Verbesserung des allgemeinen Wohlbefindens, indem es personalisierte Empfehlungen zu Schlaf-, Ess- und Trainingszeiten liefert. Das CE-zertifizierte Deep-Tech-System ist marktreif und tritt nun gemeinsam mit der Techniker Krankenkasse in den Markt ein. TimeTeller® besitzt ein enormes Marktpotenzial weit über die Onkologie hinaus. Bereits laufen Studien in den Bereichen Parkinson, Frauengesundheit, Sport und Langlebigkeit, die die vielfältigen Einsatzmöglichkeiten des Systems unterstreichen. Lassen Sie uns gemeinsam die Zukunft der personalisierten Krebsbehandlung gestalten.
Dr. Elisa KiebackChief Technology Officer – T-knife
Dr. Elisa Kieback is co-founder and Chief Technology Officer of the biotech company T-knife Therapeutics. After an academic career focused on tumor immunology and T-cell biology, she bacame the coordinator of a T-cell therapy clinical trial at the Charité in Berlin. In 2019 she founded T-knife as a spinout from the Max Delbrueck Center and the Charité. After raising the company’s Seed and Series A round, she is focused on advancing T-knife’s discovery platforms.
Dr. Fei TianPrincipal – MIG Capital
Fei is Principal in the MIG Capital Life Science investment team.
She is a healthcare innovation expert with a profound background in medicine and biology and many years of investment experience in the life science venture capital industry. Before joining MIG, Fei worked for yabeo Venture Tech and Vesalius Biocapital.
Fei studied medicine at Tongji University in PR China and worked as an emergency room physician. She then completed her doctorate in oncology and stem cell research at Ludwig-Maximilians-Universität and Klinikum.
Her membership on the Board of Directors at SciRhom, Liva, and Temedica, brings expertise in venture development and biotech value creation strategy, following the goal of enabling disruptive innovations with promises of high impact for the future of medicine.
Felix HoltermannU.S. Bureau Chief – Handelsblatt
Born in Stuttgart in 1987. Studied economics and journalism in Cologne and Auckland, New Zealand. Previous positions include „Südwest Presse“, „Süddeutsche Zeitung“ and „Frankfurter Allgemeine Zeitung“. Business editor and advisor to the radio director at the West German Broadcasting Corporation (WDR). With Handelsblatt since 2017. Banking and fintech reporter in Frankfurt, US correspondent in New York and San Francisco covering tech and automotive since 2022. State Street Institutional Press Award, German Journalism Prize, Ernst Schneider Prize, Private Media Prize, Georg von Holtzbrinck Prize, DDV Prize for Business Journalism. Author of „Geniale Betrüger – Wie Wirecard Politik und Finanzsystem bloßstellt“ (nominated for the German Business Book Award).
An dieser Stelle finden Sie Inhalte von #PROVIDER#
An dieser Stelle finden Sie Inhalte externer Anbieter, die wir für eine umfassende Informationsdarstellung zu journalistischen Zwecken einbetten. Wenn Sie diese Inhalte zulassen, werden gemäß den Datenschutzbestimmungen der jeweiligen Betreiber der externen Plattformen personenbezogene Daten übertragen und ggf. auch seitenübergreifend gesammelt und verarbeitet.
Nähere Informationen (inklusive der Links zu den Datenschutzerklärungen der externen Plattformen) finden Sie in unserer Datenschutzerklärung und unserem Privacy Manager.
